TrialPath
Recruiting

Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

NCT04537689 · Singapore General Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis Compared to Standard Care --- a Pragmatic Observational Study
About this study
First, the investigators hypothesize that a proportion of patients with moderate to severe PsO may sustain reasonable good outcomes when a short course of ixekizumab is withdrawn. Second, the investigators hypothesize that the investigators can identify the perturbations in the architecture of the immunome which are pathogenic, and to discriminate such perturbations based on treatment and clinical responses, thus distilling theragnostic signatures. Therefore, the objectives of the study are as follow: Specific aim 1: To describe the clinical course, sustained good outcomes, relapse rate, time to relapse and quality of life in PsO patients who stopped a 6-month short course treatment of ixekizumab, till the end of 2-years. Specific aim 2: To identify the genomic and immunomic signatures in skin biopsies and blood in PsO patients who has good outcomes (PASI 75) at 6 months, comparing treatment vs pragmatic control. Specific aim 3: To identify the genomic and immunomic signatures in skin biopsies and blood in PsO patients who sustained good outcomes at 1 year after stopping ixekizumab, compared to those relapsed.
Eligibility criteria
Inclusion Criteria: * Adults (\>21-year-old). * Diagnosed by dermatologist as plague-type PsO. * Having moderate to severe plague-type PsO as defined by the following: * Psoriasis Area and Severity Index (PASI) ≥12/72, * And, investigator Global Assessment Score (IGA) ≥3, * And, PsO involving body surface area involvement (BSA) ≥10% * And Candidate for phototherapy and/or systemic therapy * Topical corticosteroid up to moderate potencies are allowed * Able to provide informed consent. Exclusion Criteria: * Forms of PsO other than plaque-type. * Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the investigational product on PsO. * Evidence of active tuberculosis or other active infections (like Hepatitis C/B), malignancy; active or known use of other immunosuppressive drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit. * Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy * History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances. * Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated. * History of inflammatory bowel disease. * Pregnancy or lactating mothers. * As treatment regimen is different, participants with evidence of PsA will be excluded
Study design
Enrollment target: 40 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2020-12-10
Estimated completion: 2027-12-31
Last updated: 2022-11-25
Interventions
Biological: IxekizumabDrug: MethotrexateDrug: Cyclosporin ADrug: Acitretin
Primary outcomes
  • • Proportion of ixekizumab treated PsO participants free of relapse after ixekizumab withdrawal (12 months from ixekizumab withdrawal or 18 months from baseline.)
Sponsor
Singapore General Hospital · other
With: Translational Immunology Institute
Contacts & investigators
ContactYing Ying Leung, MD · contact · katy.leung.y.y@singhealth.com.sg · +65 63265276
ContactCynthia Ong, Bachelor · contact · cynthia.ong.s.q@sgh.com.sg · +65 65762609
InvestigatorYing Ying Leung, MD · principal_investigator, Singapore General Hospital
All locations (1)
Singapore General HospitalRecruiting
Outram Park, Singapore
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis · TrialPath